Furthermore, in metastatic cancers such as breast and ovarian cancer, low TET2 and 5hmC levels were positively correlated with the resistance of cancer cells to chemotherapeutic drugs such as PARP inhibitor olaparib and alkylating agent cisplatin [28]. Here, TET2 is linked to ovarian carcinoma.